Everything below concerns receptor agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-24. Numbers and descriptions here follow the published literature rather than marketing material.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Peptide backbone with a C18 fatty diacid side chain |
| Molecular weight | Approximately 4113 Da | Consistent with a 31-residue peptide plus linker |
| Appearance | White to off-white powder | Lyophilized solid; hygroscopic if left open |
| Solubility class | Sparingly soluble to soluble in water | Varies with pH and ionic strength |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
On one occasion, he clashed with Fripp and ordered him out of the studio. As Beat reached No. 39 in the UK and No. 52 in the US, King Crimson resumed touring. "Heartbeat" was released as a single (paired with the band's first music video), which peaked at No. 57 on the Billboard Mainstream Rock chart. Around this time the band released the VHS The Noise: Live in Frejus, a document of a show played at the Arena in Fréjus, France on 27 August 1982, co-headlining with Roxy Music (whose set from the same show was also released on VHS as The High Road). This footage was later re-released as part of the Neal and Jack and Me DVD in 2004. King Crimson's next album, Three of a Perfect Pair, was recorded in 1983 in the UK and US and released in March 1984. Having encountered difficulty in both writing and determining a direction for the album, the band chose to record and call the album's first half a "left side" – four pop-oriented songs and an instrumental – and the second, mostly-instrumental half a "right side" which contained more experimental work, improvisations that drew influence from industrial music and a third movement of "Larks' Tongues in Aspic". Stress during the writing process and the tension between the band members manifested in both lyrical content and music. The 2001 remaster of the album included an "other side", a collection of remixes and improvisational out-takes plus Levin's humorous song, "The King Crimson Barbershop". Three of a Perfect Pair peaked at No. 30 in the UK and No. 58 in the US, with the title track and "Sleepless" being released as singles.
2010: Law concerning "violence against women," within couples, with consequences for children, creating the offense of psychological domestic violence. 2011: Council of Europe Convention on preventing and combating violence against women and domestic violence. 2013: The ban on women wearing trousers is officially repealed. Wearing trousers had become common from the 1960s onward. 2014: Law for real equality between women and men. 2017: Starting January 1, 2017, a 40% quota on boards of directors or supervisory boards must be respected (for companies with a minimum number of employees or board members).
When naming a complex ion, the ligands are named before the metal ion. The ligands' names are given in alphabetical order. Numerical prefixes do not affect the order. Multiple occurring monodentate ligands receive a prefix according to the number of occurrences: di-, tri-, tetra-, penta-, or hexa-. Multiple occurring polydentate ligands (e.g., ethylenediamine, oxalate) receive bis-, tris-, tetrakis-, etc. Anions end in o. This replaces the final 'e' when the anion ends with '-ide', '-ate' or '-ite', e.g. chloride becomes chlorido and sulfate becomes sulfato. Formerly, '-ide' was changed to '-o' (e.g. chloro and cyano), but this rule has been modified in the 2005 IUPAC recommendations and the correct forms for these ligands are now chlorido and cyanido. Neutral ligands are given their usual name, with some exceptions: NH3 becomes ammine; H2O becomes aqua or aquo; CO becomes carbonyl; NO becomes nitrosyl. Write the name of the central atom/ion. If the complex is an anion, the central atom's name will end in -ate, and its Latin name will be used if available (except for mercury). The oxidation state of the central atom is to be specified (when it is one of several possible, or zero), and should be written as a Roman numeral (or 0) enclosed in parentheses. Name of the cation should be preceded by the name of anion. (if applicable, as in last example) Examples:
The American Kestrel Partnership developed and maintains a web-based network for citizen and professional scientists to enter, manage, and consolidate data from kestrel nest box monitoring programs in the Western Hemisphere. The database is being used by researchers to model and understand relationships between kestrel nesting parameters (e.g., phenology, occupancy, survival, productivity, and nestling weight and exposure to environmental toxins) and environmental factors, such as land use, landscape composition and configuration, climate conditions (e.g., drought), and point sources of environmental toxins. Each breeding season, the American Kestrel Partnership features a live-streaming video feed from the nest box located at The Peregrine Fund's campus in Boise, Idaho.
Sources: en.wikipedia.org
Is it morally right to tamper with nature? Is one playing God when creating new life? What happens if a synthetic organism accidentally escapes? What if an individual misuses synthetic biology and creates a harmful entity (e.g., a biological weapon)? Who will have control of and access to the products of synthetic biology? Who will gain from these innovations? Investors? Medical patients? Industrial farmers? Does the patent system allow patents on living organisms? What about parts of organisms, like HIV resistance genes in humans? What if a new creation is deserving of moral or legal status? The ethical aspects of synthetic biology has three main features: biosafety, biosecurity, and the creation of new life forms. Other ethical issues mentioned include the regulation of new creations, patent management of new creations, benefit distribution, and research integrity. Ethical issues have surfaced for recombinant DNA and genetically modified organism (GMO) technologies and extensive regulations of genetic engineering and pathogen research were in place in many jurisdictions. Amy Gutmann, former head of the Presidential Bioethics Commission, argued that we should avoid the temptation to over-regulate synthetic biology in general, and genetic engineering in particular. According to Gutmann, "Regulatory parsimony is especially important in emerging technologies...where the temptation to stifle innovation on the basis of uncertainty and fear of the unknown is particularly great.
has served on the Council of the British Records Association (1989–2005); the Council of the Royal Historical Society (1993–1996 and 1997–2000); and the Council of the List and Index Society (from 1997); has sat on the editorial boards of History Today, International History Review, Journal of Military History, Media History and the Journal of the Royal United Service Institution (now the RUSI Journal); awarded Samuel Eliot Morison Prize for lifetime achievement by the Society for Military History. Anthony Blond (20 March 1928 – 27 February 2008) publisher and author involved with several publishing companies over his career; of Sephardi ancestry; cousin of Harold Laski. Heston Blumenthal celebrity chef and author of over five books, was born in Shepherd's Bush, London, on 27 May 1966, to a Jewish father born in Southern Rhodesia and an English mother who converted to Judaism. His surname comes from a great-grandfather from Latvia and means 'flowered valley' (or 'bloom-dale'), in German.
Liver Function Tests at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Liver Function Tests at Lab Tests Online Overview at Mayo Clinic Abnormal Liver Function Tests Archived 11 April 2012 at the Wayback Machine Overview of liver enzymes Abnormal Liver Tests Curriculum at AASLD Further workup of abnormal liver tests: "etiology panel"
Paroxetine is a constrained structural analogue of fluoxetine where the linear phenylpropylamine group of fluoxetine has been folded into a piperidine ring (figure 5). The compound has the possibility of four stereoisomers because it contains two chiral centers, but one of them, the (3S,4R)-isomer, is marketed as paroxetine. Research has shown that stereochemical factors affect affinity of the molecule for SERT where substitution into the 2-ortho-position of either aromatic rings decreases affinity for rat SERT by as much as 10–100 times, where the greatest loss occurs in the phenoxy ring. Paroxetine is the most potent SSRI drug available, but it is less selective for SERT than fluvoxamine and sertraline. Paroxetine also has weak NET inhibition which could contribute to its efficacy in depression, especially at higher doses. As demonstrated in table 2, paroxetine also inhibits the NOSs enzyme which could be the reason for its sexual dysfunction adverse effect, especially in men. Paroxetine shows the highest affinity for muscarinic receptors of all the SSRIs which results in weak anticholinergic activity and therefore undesirable adverse effects.
Deploying a COVID‑19 vaccine may require worldwide transport and tracking of 10–19 billion vial doses, an effort readily becoming the largest supply chain challenge in history. As of September 2020, supply chain and logistics experts expressed concern that international and national networks for distributing a licensed vaccine were not ready for the volume and urgency, due mainly to deterioration of resources during 2020 pandemic lockdowns and downsizing that degraded supply capabilities. Globally, supplies critical to vaccine research and development are increasingly scarce due to international competition or national sequestration. Addressing the worldwide challenge faced by coordinating numerous organizations – the COVAX partnership, global pharmaceutical companies, contract vaccine manufacturers, inter- and intranational transport, vaccine storage facilities, and health organizations in individual countries – Seth Berkley, chief executive of GAVI, stated: "Delivering billions of doses of vaccine to the entire world efficiently will involve hugely complex logistical and programmatic obstacles all the way along the supply chain." As an example highlighting the immensity of the challenge, the International Air Transport Association stated that 8,000 Boeing 747 cargo planes, equipped for precision vaccine cold storage, would be needed to transport one dose for the entire population in the more than 200 countries experiencing the COVID‑19 pandemic.
Sources: en.wikipedia.org
=== Violent depictions of mental illness === The negative stigma that surrounds mental illness has real-life consequences for those who experience these illnesses. Many studies, both in the form of experimental designs and surveys, have concluded that media exposure does affect the stigmatization of mental illness. Despite the media's common depictions of mentally ill characters being violent or engaging in criminal activities, it is much less common in the real world than the media makes it seem. Of the 40+ million people in the U.S. who are classified as experiencing mental illness, violence or criminality occurs only in 10-12% of mental illness cases. However, as film and television programs utilize this trope for dramatic storytelling, the public often falsely assumes that the real world mirrors the mass media depictions. Scholars began analyzing this trend in the 1950s, yet the issue persists into the 21st century. In the late 1950s, the concern regarding mass media portrayals of mental illness started becoming more prominent. At the time, television network censors were used to determine the level of viewing (adults only, family-friendly, or needed altered content) that was appropriate based on the film's content. George Gerbner, before he developed cultivation theory, studied the films that were censored and found that in 1951, only five films contained representations of mental illness. However, by 1957, the number rose to 170 films, demonstrating the growing concern over misrepresentations and their effects.
== See also == Babesiosis Biliary atresia Bilirubin diglucuronide Biliverdin Crigler–Najjar syndrome Gilbert's syndrome, a genetic disorder of bilirubin metabolism that can result in mild jaundice, found in about 5% of the population. Hy's Law Lumirubin Primary biliary cholangitis Primary sclerosing cholangitis
It is critical that the sample be processed before entering the mass spectrometer so that only a single chemical species enters at a given time. Generally, samples are combusted or pyrolyzed and the desired gas species (usually hydrogen (H2), nitrogen (N2), carbon dioxide (CO2), or sulfur dioxide (SO2)) is purified by means of traps, filters, catalysts and/or chromatography. The two most common types of IRMS instruments are continuous flow and dual inlet. In dual inlet IRMS, purified gas obtained from a sample is alternated rapidly with a standard gas (of known isotopic composition) by means of a system of valves, so that a number of comparison measurements are made of both gases. In continuous flow IRMS, sample preparation occurs immediately before introduction to the IRMS, and the purified gas produced from the sample is measured just once. The standard gas may be measured before and after the sample or after a series of sample measurements. While continuous-flow IRMS instruments can achieve higher sample throughput and are more convenient to use than dual inlet instruments, the yielded data is of approximately 10-fold lower precision.
Over time standards of refrigerator energy efficiency have been introduced and tightened, which has driven steady improvement; 21st-century refrigerators are typically three times more energy-efficient than in the 1930s. The efficiency of older refrigerators can be improved by regular defrosting (if the unit is manual defrost) and cleaning, replacing deteriorated door seals with new ones, not setting the thermostat colder than actually required (a refrigerator does not usually need to be colder than 4 °C (39 °F)), and replacing insulation, where applicable. Cleaning condenser coils to remove dust impeding heat flow, and ensuring that there is space for air flow around the condenser can improve efficiency.
== Operation Atlantic Resolve == On 29 March 2017, the Department of Defense reported that Green Berets from 1st Battalion 10th SFG were deployed to Europe to take part in exercise Allied Spirit VI-a multinational training exercise involving military personnel from Canada, Czech Republic, Estonia, Finland, France, Hungary, Germany, Italy, Macedonia, Kosovo, Latvia, the Netherlands, Slovenia, UK and US at the JMRC in Germany, the exercise involved special operations and conventional forces with the aim to increase their effectiveness and/particularly to increase the effectiveness of special operations forces in working together while bolstering the capabilities of partner nations within US European Command's area of responsibility. The Green Berets provided their advise and assist training/skills, whilst working with Estonian Special Operations Task Group troops and Macedonian special operations troops. US Army Major Robert Temple, the special operations force cell planner at the JMRC said that “The primary purpose of this exercise is providing a venue for the 1st Latvian Brigade to train in a Joint Task Force environment and increase their interoperability with both U.S. units as well as other multinational forces.” The exercise is being conducted as part of Operation Atlantic Resolve.
Sources: en.wikipedia.org
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.
Structural modifications, including a fatty acid side chain and non-natural amino acid substitutions, slow enzymatic breakdown and promote albumin binding. These changes support once-weekly dosing rather than twice-daily administration.
The pathways involving insulin, glucagon, gastric emptying, and appetite signaling are well described. How much each pathway contributes to weight reduction in a given person is not fully established.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.